Farampator - CAS 211735-76-1
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C12H13N3O2
Molecular Weight:
231.25
COA:
Inquire
Targets:
AMPAR
Description:
Farampator, also called as CX-691 or Org24448, is an AMPA receptor positive allosteric modulator and glycine reuptake inhibitor potentially for the treatment of schizophrenia.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
An AMPA receptor positive modulator and glycine reuptake inhibitor
Synonyms:
2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone; 1-(benzofurazan-5-ylcarbonyl)piperidine; 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole ;CX-691; farampator; Org 24448
Solubility:
DMSO: ≥ 34 mg/mL
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Boiling Point:
398.3±34.0 ℃ at 760 Torr
Density:
1.299±0.06 g/cm3
InChIKey:
XFVRBYKKGGDPAJ-UHFFFAOYSA-N
InChI:
1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2
Canonical SMILES:
C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
1.Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
Vale S1. Exp Biol Med (Maywood). 2008 Aug;233(8):941-51. doi: 10.3181/0707-MR-193. Epub 2008 Jun 5.
Parkinson's disease (PD) clinical features comprise both motor and nonmotor manifestations. Among the nonmotor complications, dementia is the most important. Approximately 40% of PD patients are affected by cognitive impairment. Remarkably, in addition to age, dementia is an independent predictor of mortality, whereas age at onset of PD and severity of neurological symptoms are not. In this review, I summarize the current knowledge of the pathogenesis of the PD cognitive impairment in relation to the therapies presently accessible and those that could become strategic in the near future. It is hypothesized that patients with PD show two components of cognitive dysfunction (CD): a generalized profile of subcortical dementia (PDsCD), and an overlapped pattern suggesting specific prefrontal damage with CD (PDpFCD). PDsCD is associated with structural neocortical/subcortical changes in the brain (in frontal, parietal, limbic, and temporal lobes, as well as in midbrain structures).
2.Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.
Woolley ML1, Waters KA, Gartlon JE, Lacroix LP, Jennings C, Shaughnessy F, Ong A, Pemberton DJ, Harries MH, Southam E, Jones DN, Dawson LA. Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54. doi: 10.1007/s00213-008-1325-2. Epub 2008 Sep 16.
RATIONALE: Positive allosteric modulators of the glutamatergic alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptor do not stimulate AMPA receptors directly but delay deactivation of the receptor and/or slow its desensitisation. This results in increased synaptic responses and enhanced long-term potentiation. Thus, it has been suggested that such compounds may have utility for the treatment of cognitive impairment.
3.Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers.
Wezenberg E1, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. Epub 2006 Nov 22.
Ampakines act as positive allosteric modulators of AMPA-type glutamate receptors and facilitate hippocampal long-term potentiation (LTP), a mechanism associated with memory storage and consolidation. The present study investigated the acute effects of farampator, 1-(benzofurazan-5-ylcarbonyl) piperidine, on memory and information processes in healthy elderly volunteers. A double-blind, placebo-controlled, randomized, cross-over study was performed in 16 healthy, elderly volunteers (eight male, eight female; mean age 66.1, SD 4.5 years). All subjects received farampator (500 mg) and placebo. Testing took place 1 h after drug intake, which was around Tmax for farampator. Subjects performed tasks assessing episodic memory (wordlist learning and picture memory), working and short-term memory (N-back, symbol recall) and motor learning (maze task, pursuit rotor). Information processing was assessed with a tangled lines task, the symbol digit substitution test (SDST) and the continuous trail making test (CTMT).
4.Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Jardemark K1, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Psychopharmacology (Berl). 2012 May;221(1):115-31. doi: 10.1007/s00213-011-2554-3. Epub 2011 Nov 9.
RATIONALE: The α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor positive allosteric modulators (AMPA-PAMs), Org 24448 and Org 26576, and the glycine transporter-1 (GlyT-1) inhibitor Org 25935 are developed for treatment of schizophrenia.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AMPAR Products


CAS 161832-65-1 Talampanel

Talampanel
(CAS: 161832-65-1)

Talampanel, also known as LY300164 and GYKI-53773, is a glutamate receptor inhibitor with anti-seizure activity. Talampanel is also an orally active, potent an...

CAS 140187-23-1 (S)-(-)-5-Fluorowillardiine

(S)-(-)-5-Fluorowillardiine
(CAS: 140187-23-1)

A more potent and selective AMPA receptor agonist (at hGluR1 and hGluR2) than AMPA itself (Ki = 14.7, 25.1, and 1820 nM for hGluR1, hGluR2 and hGluR5 respective...

CAS 380607-77-2 CMPDA

CMPDA
(CAS: 380607-77-2)

CMPDA is a positive allosteric modulator of AMPA receptors. Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.

CAS 154235-83-3 Ampalex

Ampalex
(CAS: 154235-83-3)

CX516 is a positive allosteric modulator at AMPA receptor that inhibits the deactivation of AMPA receptors. CX-516 is a nootropic and ampakine agent.

GYKI 47261 dihydrochloride
(CAS: 1217049-32-5)

This active molecular is Non-competitiv a AMPA antagonist with IC50 value of 2.5 μM. GYKI-47261 is also a CYP2E1 inducer. GYKI-47261 showed broad spectrum of an...

CAS 157115-85-0 Noopept

Noopept
(CAS: 157115-85-0)

Noopept is a nootropic and neuroprotective drug that normalizes the balance of the pro- and antioxidant systems. Noopept modulates a variety of physiological fu...

CAS 199655-36-2 CP 465022

CP 465022
(CAS: 199655-36-2)

CP 465022, with anticonvulsant activity, is a potent, brain penetrant, orally active and selective noncompetitive AMPA receptor antagonist (IC50 = 25 nM in rat ...

GYKI 53784
(CAS: 161832-71-9)

GYKI-53784, a dioxolbenzene derivative, has been found to be a AMPA receptor antagonist that could block excitotoxicity and decrease auditory nerve activity at ...

EGIS-8332
(CAS: 220725-87-1)

EGIS-8332 potently decreased AMPA and quisqualate induced LDH release (IC50 = 5.2 ± 0.4 and 7.4 ± 1.3 μM, respectively) from the cells. The inhibition of the AM...

CAS 178616-26-7 CFM-2

CFM-2
(CAS: 178616-26-7)

Potent and selective AMPA antagonist.

CAS 141286-78-4 PEPA

PEPA
(CAS: 141286-78-4)

2,6-Difluoro-4-[2-(phenylsul­fonyl­amino)­ethyl­thio]­phenoxy­acet­amide is a structurally novel, selective, high affinity AMPA ionotropic glutamate receptor ag...

CAS 122306-11-0 Naspm

Naspm
(CAS: 122306-11-0)

A poliamine amide as potent Spermidine uptake inhibitor.

GYKI-52466
(CAS: 102771-26-6)

GYKI-52466 is a non-competitive AMPA receptor antagonist. It belongs to 2,3-benzodiazepine that acts as an ionotropic glutamate receptor antagonist. It has anti...

CAS 154652-83-2 Tezampanel

Tezampanel
(CAS: 154652-83-2)

Tezampanel, a decahydroisoquinoline derivative, has been found to be AMPA receptor as well as Kainic acid receptor antagonist that could probably be useful in s...

CAS 72432-10-1 Aniracetam

Aniracetam
(CAS: 72432-10-1)

Aniracetam is a nootropics and neuroprotective drug.

NS-1209
(CAS: 245063-59-6)

NS-1209, an AMPA/GluR5 receptor antagonist, is a antiepileptic drug candidate currently under clinical trials.

CAS 215923-54-9 CX546

CX546
(CAS: 215923-54-9)

It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine dru...

CAS 220445-20-5 GYKI-47261

GYKI-47261
(CAS: 220445-20-5)

GYKI-47261 is a non-competitive AMPA receptor antagonist (IC50 = 2.5 μM) and a CYP2E1 inducer. GYKI-47261 shows broad spectrum anticonvulsive activity and neuro...

CAS 375345-95-2 LY451395

LY451395
(CAS: 375345-95-2)

Incubation of LY451395 with Actinoplanes missouriensis NRRL B3342 generated several metabolites that were previously detected in the in vivo metabolism studies ...

CAS 376594-67-1 LY450108

LY450108
(CAS: 376594-67-1)

AMPA receptors mediate most of the excitatory neurotransmission and play a key role in synaptic plasticity in the mammalian central nervous system (CNS). Recent...

Chemical Structure

CAS 211735-76-1 Farampator

Quick Inquiry

Verification code

Featured Items